Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Resistance to immune-checkpoint blockade often occurs in treated patients. Here, the authors demonstrate that B2M loss is a mechanism of primary and acquired resistance to therapies targeting CTLA4 or PD-1 in melanoma patients.
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-10-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-017-01062-w |